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There are significant variations in the HIV rates in the
countries of Eastern Europe and Central Asia, with about
90% of all regional HIV burden concentrated in Russia
and Ukraine. Given the start of HIV epidemic in the region
in the second half of the 1990s, at the moment many
countries are seeing a rapid rise in the number of people
in need of life-saving antiretroviral therapy (ART). Due to
the grants of the Global Fund and, in some countries
increase in domestic HIV funding, over the last 3–4 years
there has been a considerable improvement in availability
of ART in the region. The downside of that positive devel-
opment, however, is that the rapid scale-up of ambitious
AIDS control projects requiring uninterrupted supply of
ARV drugs and qualified work force often represents a
major challenge for many countries of the region given
their weak health systems and poor managerial capacity.
Other main current barriers that are specific for the region
can be roughly grouped into three areas. Firstly, epidemi-
ological challenges originating from the concentration of
the majority of HIV cases among injecting drug users
whom traditional health institutions find difficult to con-
tact, recruit and retain in treatment. Secondly, clinical
challenges like high rate of co-infection of HIV with tuber-
culosis, hepatitis B and C, as well as drug dependency.
Thirdly, organizational challenges in the form of the ver-
tical AIDS programs and unprepared general health serv-
ices resulting in serious limitation of geographical
coverage of ART programs. This is also compounded by
methodological issues, like existing controversy among
local professionals over many adjuvant interventions with
the effectiveness proven elsewhere, e.g. preventive izoni-
azide treatment, substitution treatment, etc. The future
challenges for the region will also probably include grad-
ual increase in drug resistance and long-term sustainabil-
ity, as more and more countries of Eastern Europe and
Central Asia become ineligible for HIV grants from
GFATM.
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